MedTrace Logo

Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor

NCT03023124 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2024-12-09

No results posted yet for this study

Summary

Phase II randomized study for the comparison of trabectedin versus doxorubicin plus dacarbazine in patients with advanced solitary fibrous tumor

Conditions

  • Solitary Fibrous Tumors

Interventions

DRUG

Trabectedin

Treatment with trabectedin repeated every 21 days for 6 cycles

DRUG

Adriamycin

Treatment with Adriamycin at day 1 every 21 days for 6 cycles

DRUG

Dacarbazine

Treatment with Dacarbazine at days 1 and 2 every 21 days for 6 cycles

Sponsors & Collaborators

  • Italian Sarcoma Group

    lead NETWORK

Principal Investigators

  • Silvia Stacchiotti, MD · Italian Sarcoma Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-04
Primary Completion
2024-12-06
Completion
2024-12-06

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03023124 on ClinicalTrials.gov